167 related articles for article (PubMed ID: 24893616)
1. FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.
L'Abbate A; Lo Cunsolo C; Macrì E; Iuzzolino P; Mecucci C; Doglioni C; Coco M; Muscarella LA; Salati S; Tagliafico E; Minoia C; De Tullio G; Guarini A; Testoni N; Agostinelli C; Storlazzi CT
BMC Cancer; 2014 Jun; 14():396. PubMed ID: 24893616
[TBL] [Abstract][Full Text] [Related]
2. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
3. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
[TBL] [Abstract][Full Text] [Related]
4. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
5. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
[TBL] [Abstract][Full Text] [Related]
8. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
9. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
10. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
12. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
[TBL] [Abstract][Full Text] [Related]
13. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
14. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Göhring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellström-Lindberg E
Haematologica; 2014 Jun; 99(6):1041-9. PubMed ID: 24682512
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
[TBL] [Abstract][Full Text] [Related]
16. New complex t(2;11;17)(p21;q23;q11), a variant form of t(2;11), associated with del(5)(q23q32) in myelodysplastic syndrome-derived acute myeloblastic leukemia.
Yamamoto K; Nagata K; Morita Y; Inagaki K; Hamaguchi H
Cancer Genet Cytogenet; 2002 Sep; 137(2):119-23. PubMed ID: 12393282
[TBL] [Abstract][Full Text] [Related]
17. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
[TBL] [Abstract][Full Text] [Related]
18. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
[TBL] [Abstract][Full Text] [Related]
19. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Göhring G; Giagounidis A; Büsche G; Hofmann W; Kreipe HH; Fenaux P; Hellström-Lindberg E; Schlegelberger B
Haematologica; 2011 Feb; 96(2):319-22. PubMed ID: 21109690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
